Morgan Stanley projects Eli Lilly’s GLP-1 franchise will outperform 2026 consensus forecasts.
The firm estimates 2026 worldwide revenue at $60.3 billion. This projection exceeds the current consensus estimate of $55.6 billion.
Mounjaro sales outperformed estimates for four consecutive quarters. Growth is driven by rising obesity treatment adoption and delayed generic competition in key markets.
Morgan Stanley reiterated its Overweight rating on the stock. The investment bank maintained its $1,344 price target.